Trump Bans CNN, MS NOW and Politico From White House 
Meta Partners With Shopify to Bring Shop Pay Checkout to Muse AI 
OpenAI Urges US-Led Global Standards for Frontier AI 
Bessent, He Lifeng to Discuss AI Security and Trade in New York 
SoftBank Launches $11 Billion Bond Sale to Fund OpenAI Investment 
Bolivia Approves $1.9 Billion IMF Financing Deal 
Wall Street Mixed as Treasury Yields Rise After Fed Hike 
France Debt-to-GDP Ratio Seen Hitting Record 119.3% in 2026 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Gold Prices Hold Steady Ahead of Trump-Xi Summit, Middle East Risks 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
Vietnam, US Trade Deal Could Be Signed Soon, To Lam Says 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
Europe Jet Fuel Deficit Drives South Korean Imports to Four-Year High 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Add as a preferred source on Google
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
